Monday, June 8, 2026

KFF released its annual Medicare Advantage report for 2026. It details changes to average premiums, out-of-pocket limits, and the spread of supplemental benefits. The report also notes continued use of prior authorization across plans, a persistent friction point for practices. For billing teams, this serves as a 2026 plan-year reference. Monitor plan-specific documents from your MA payers now; benefits, networks, and cost-sharing details finalize ahead of the Annual Enrollment Period starting October 15. Use this data to inform patient conversations and anticipate potential claim and authorization workflows.

RCM firm Med-Metrix acquired coding and charge capture company Vitalware. The deal aims to integrate Vitalware's coding accuracy and CDI tools to improve clients' net revenue yield. This reflects ongoing consolidation in the RCM technology and services sector, where firms are building broader platforms. For independent practices, it signals a continued shift toward integrated, tech-enabled revenue cycle solutions from larger vendors. Evaluate whether your current RCM partner's roadmap includes similar investments in automated coding and CDI, as these are becoming table stakes for denial prevention.

Cigna has dropped coverage for GLP-1 obesity drugs, including Wegovy and Zepbound, from its own employee health plan, citing cost. This follows Cigna's earlier move to exclude the drugs for its PBM employer clients. The decision reflects the intense cost pressure these drugs place on commercial plans. For practices with Cigna commercial patients, expect increased prior authorization scrutiny and potential denials for GLP-1 prescriptions for obesity. Verify patient-specific pharmacy benefits before prescribing and prepare robust documentation of medical necessity, including comorbid conditions.

The Senate approved legislation to eliminate administrative hurdles for opioid use disorder treatment, including prior authorization requirements for medication-assisted treatment (MAT). The bill specifically targets Medicaid and state-regulated health plans, mandating coverage for FDA-approved MAT drugs without preauthorization. For practices providing addiction medicine, this reduces billing friction for buprenorphine and naltrexone prescriptions starting with the 2027 plan year. The legislation mirrors similar provisions in the SUPPORT Act but extends them to all state Medicaid programs. Billing teams should prepare for smoother claims submission for MAT services after the effective date, though verification of state-level implementation remains necessary.

CMS has released detailed guidance for states implementing Medicaid work requirements, targeting a 2027 operational deadline. The rule establishes an 80-hour monthly work mandate for able-bodied adults aged 19–64, with narrow exemptions for pregnancy, disability, and primary caregivers. States must submit implementation plans by Q4 2026. For practices serving Medicaid populations, this signals potential enrollment churn and coverage disruptions as beneficiaries navigate reporting requirements. The policy could reduce patient volume in states that aggressively adopt the requirements. Monitor your state Medicaid agency's proposal and prepare front-office staff for eligibility verification challenges starting mid-2027.